IFNG and neoplasm: Pharmacological inhibition of HSD11B1 protects against immune surveillance and the tumour‐killing capability of TILs and increases IFN‐γ signalling to induce immune checkpoint inhibitor (ICI) responses but possibly exacerbate the risk of immune‐related adverse events (irAEs).176